Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine
A Randomized, Partially Blinded, Positively Controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine in a Population Aged 2 Months and Older
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
- Biological: Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine
- Biological: Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine
- Biological: Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine
- Biological: Haemophilus Influenzae Type b Conjugate Vaccine
- Biological: Haemophilus Influenzae Type b Conjugate Vaccine
- Biological: Haemophilus Influenzae Type b Conjugate Vaccine
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Haojie Liu
- Phone Number: 022-58213600-6051
- Email: haojie.liu@cansinotech.com
Study Contact Backup
- Name: Qing Wang
- Email: 576801380@qq.com
Study Locations
-
-
-
Chongqing, China
- Jiulongpo District Center for Disease Control and Prevention
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects aged 2 months, 6-11 months, 1-5 years, and 18-59 years at the time of screening
- Informed consent is obtained from the subject and the subject and/or guardian (attorney-in-fact) is able to sign the informed consent form
- Subjects are able and willing to comply with the requirements of the clinical trial protocol and are able to complete the full study follow up
Exclusion criteria for first dose:
- 2 months old, 6 months old ~ 5 years old people have been vaccinated with Hib-containing vaccines
- 2-month-old, 6~11-month-old infants who were born prematurely (delivered before the 37th week of gestation), low birth weight (birth weight <2500g)
- 2-month-old, 6~11-month-old infants with abnormal labor and delivery, history of asphyxia rescue, history of neurological damage
- Those with history of Haemophilus influenzae type b infection
- Those with history of epilepsy, convulsions, convulsions, cerebral palsy, or history of psychiatric illness or family history or other progressive neurological diseases
- Have been diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), juvenile rheumatoid arthritis (JRA), or other autoimmune diseases
- History of allergy to vaccines or vaccine components, severe side effects to vaccines such as urticaria, dyspnea, angioneurotic edema
- Female with positive urine pregnancy test or breastfeeding subjects, subjects or their partners with pregnancy plan within 6 months (only for 18~59 years old)
- Fever with axillary temperature > 37.0°C
- Known or suspected to be suffering from acute diseases or serious chronic diseases (including: serious respiratory diseases, serious cardiovascular diseases, liver and kidney diseases, serious skin diseases, malignant tumors, tuberculosis, etc.); or in the acute exacerbation of chronic diseases
- Those who have hypertension that cannot be controlled by medication (at the time of on-site measurement: systolic blood pressure ≥160 mmHg and diastolic blood pressure ≥100 mmHg) (only applicable to 18~59 years old)
- Any of the routine blood biochemistry indexes during the screening period judged to be clinically significant by the investigator (only applicable to 2~5, 18~59 years old)
- Have no spleen or functional absence of spleen
- Suffering from thrombocytopenia, bleeding disorders, or other coagulation disorders (which may cause contraindication to intramuscular injection)
- Immunosuppressive therapy, anti-allergy therapy, cytotoxic therapy, inhaled corticosteroids (excluding corticosteroid spray therapy for allergic rhinitis, surface corticosteroids for acute uncomplicated dermatitis) within the past 6 months
- Received blood products within 3 months prior to receiving the experimental drug
- Participation in other studies involving interventional studies within 1 month prior to receiving the investigational drug and/or during the study participation period
- Having received an injectable live attenuated vaccine within 14 days or another vaccine within 7 days prior to vaccination
- In the judgment of the investigator, due to a variety of medical, psychological, social or other conditions that are contrary to the trial protocol or that affect the subject's ability to sign informed consent
Exclusion criteria for subsequent doses
- A vaccine-related serious adverse event occurred after the previous dose of vaccination
- Who has experienced a Grade 3 or higher allergic reaction related to the vaccine after the previous dose of vaccination
- Any other factors that, in the judgment of the investigator, make the subject unsuitable for continued participation in the clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Experimental vaccine group 1A
Subjects aged 18-59 years
|
1 dose (0.5ml) of vaccine on day 0, Intramuscular injection
3 doses (0.5ml per dose) at day 0, 1 month, and 18 months of age, Intramuscular injection
4 doses (0.5ml per dose) at day 0, 2, 4 month, and 18 months of age, Intramuscular injection
|
|
Experimental: Experimental vaccine group 2A
Subjects aged 1-5 years
|
1 dose (0.5ml) of vaccine on day 0, Intramuscular injection
3 doses (0.5ml per dose) at day 0, 1 month, and 18 months of age, Intramuscular injection
4 doses (0.5ml per dose) at day 0, 2, 4 month, and 18 months of age, Intramuscular injection
|
|
Active Comparator: Control vaccine group 2B
Subjects aged 1-5 years
|
1 dose (0.5ml) of vaccine on day 0, Intramuscular injection
3 doses (0.5ml per dose) at day 0, 1 month, and 18 months of age, Intramuscular injection
4 doses (0.5ml per dose) at day 0, 2, 4 month, and 18 months of age.
Intramuscular injection
|
|
Experimental: Experimental vaccine group 3A
Subjects aged 6-11 months
|
1 dose (0.5ml) of vaccine on day 0, Intramuscular injection
3 doses (0.5ml per dose) at day 0, 1 month, and 18 months of age, Intramuscular injection
4 doses (0.5ml per dose) at day 0, 2, 4 month, and 18 months of age, Intramuscular injection
|
|
Active Comparator: Control vaccine group 3B
Subjects aged 6-11 months
|
1 dose (0.5ml) of vaccine on day 0, Intramuscular injection
3 doses (0.5ml per dose) at day 0, 1 month, and 18 months of age, Intramuscular injection
4 doses (0.5ml per dose) at day 0, 2, 4 month, and 18 months of age.
Intramuscular injection
|
|
Experimental: Experimental vaccine group 4A
Subjects aged 2 months
|
1 dose (0.5ml) of vaccine on day 0, Intramuscular injection
3 doses (0.5ml per dose) at day 0, 1 month, and 18 months of age, Intramuscular injection
4 doses (0.5ml per dose) at day 0, 2, 4 month, and 18 months of age, Intramuscular injection
|
|
Active Comparator: Control vaccine group 4B
Subjects aged 2 months
|
1 dose (0.5ml) of vaccine on day 0, Intramuscular injection
3 doses (0.5ml per dose) at day 0, 1 month, and 18 months of age, Intramuscular injection
4 doses (0.5ml per dose) at day 0, 2, 4 month, and 18 months of age.
Intramuscular injection
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Adverse reactions in all subjects
Time Frame: Within 30 days of each dose of vaccine
|
Within 30 days of each dose of vaccine
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Adverse reactions in all subjects
Time Frame: Within 30 minutes of each dose of vaccine
|
Within 30 minutes of each dose of vaccine
|
|
Adverse events in all subjects
Time Frame: Within 30 days of each dose of vaccine
|
Within 30 days of each dose of vaccine
|
|
Incidence of SAEs in all subjects
Time Frame: From the first dose to 6 months after full vaccination
|
From the first dose to 6 months after full vaccination
|
|
Incidence of abnormal and clinically significant (CS) white blood cell counts, hemoglobin, platelet counts, Alanine aminoTransferase (ALT), Aspartate Transaminase (AST), and TBIL assays in subjects 18-59, 2-5 years of age
Time Frame: Day 8 post-immunization
|
Day 8 post-immunization
|
|
Proportion of 2-month-old subjects with anti-Hib-PRP antibody concentrations ≥1.0 μg/ml
Time Frame: 30 days after basic immunization, before booster immunization, 30 days after booster immunization
|
30 days after basic immunization, before booster immunization, 30 days after booster immunization
|
|
Positive transfer rate of anti-Hib-PRP antibodies in 2-month-old subjects
Time Frame: 30 days after basic immunization, before booster immunization, 30 days after booster immunization
|
30 days after basic immunization, before booster immunization, 30 days after booster immunization
|
|
Positivity of anti-Hib-PRP antibodies in 2-month-old subjects
Time Frame: 30 days after basic immunization, before booster immunization, 30 days after booster immunization
|
30 days after basic immunization, before booster immunization, 30 days after booster immunization
|
|
Geometric Mean Concentration (GMC) of anti-Hib-PRP antibodies in 2-month-old subjects
Time Frame: 30 days after basic immunization, before booster immunization, 30 days after booster immunization
|
30 days after basic immunization, before booster immunization, 30 days after booster immunization
|
|
Geometric Mean Increase (GMI) of anti-Hib-PRP antibodies in 2-month-old subjects
Time Frame: 30 days after basic immunization, before booster immunization, 30 days after booster immunization
|
30 days after basic immunization, before booster immunization, 30 days after booster immunization
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Hongying Li, Chongqing Center for Disease Control and Prevention (Chongqing Academy of Preventive Medicine)
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CTP-DHMCV-003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.